Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces extracellular adenosine (eADO), which not only inhibits antitumor T cell activity via the adenosine receptor (AR) A(2A)R, but also enhances t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurago, Zoya, Guo, Gang, Shi, Huidong, Bollag, Roni J., Groves, Michael W., Byrd, J. Kenneth, Cui, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330720/
https://www.ncbi.nlm.nih.gov/pubmed/37435071
http://dx.doi.org/10.3389/fimmu.2023.1212209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330720/
https://www.ncbi.nlm.nih.gov/pubmed/37435071
http://dx.doi.org/10.3389/fimmu.2023.1212209

Ejemplares similares